GoodRx Holdings’ latest price target update reflects a slightly higher discount rate and a modestly lower revenue growth outlook, even as the fair value estimate remains steady at $5.09 per share. These tweaks capture a market narrative that balances new partnership-driven opportunities with ongoing uncertainties in the pharmacy and PBM landscape. Stay tuned to see how investors and analysts can track these evolving assumptions to stay ahead of the shifting story around GoodRx.

Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value GoodRx Holdings.

???? Bullish Takeaways

Citi reiterates a Buy rating with a $5.75 target, viewing a potential TrumpRx partnership as welcome news that could leverage GoodRx's pricing platform within a broader direct to consumer drug channel.

TD Cowen maintains a Buy rating, even after trimming its target to $6 from $7, arguing that the current share price overly discounts a weaker near term outlook relative to long term opportunities, including GoodRx's role in Cigna's new PBM model and new product offerings.

Several bullish and neutral analysts acknowledge GoodRx's improving execution around partnerships, including expanding relationships with Novo Nordisk and potential government aligned platforms, as a key strategic growth driver even if material financial impact is expected further out.

???? Bearish Takeaways

BofA remains firmly cautious, cutting its target to $3 from $3.40 and maintaining an Underperform rating, arguing that pharmacy closures, reimbursement pressure, and structural shifts in drug pricing undermine GoodRx's legacy discount card economics and weigh on medium term growth.

In separate commentary, BofA reiterates that the popping of the gross to net bubble in drug pricing is a negative for GoodRx's original business model, framing future success as contingent on navigating a rapidly evolving policy and PBM landscape.

Mizuho lowers its target to $4 from $5 while keeping a Neutral stance, signaling that valuation must reflect slower growth and execution risk until GoodRx proves that newer initiatives can offset industry headwinds and re accelerate revenue momentum.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

Reuters reports that GoodRx and several retail pharmacies have explored potential participation in the TrumpRx platform ahead of its planned 2026 launch, signaling interest in expanded roles within emerging federal drug purchasing channels.

According to CBS News, GoodRx will not move forward with a TrumpRx partnership. The federal site will instead route consumers directly to pharmaceutical company websites for purchases, narrowing near term expectations for GoodRx's involvement in federal discount programs.

The Wall Street Journal notes that GoodRx is among the companies investors are watching as BlinkRx, connected to Donald Trump Jr., prepares a major summit for drugmakers focused on direct to consumer models. This raises questions about how shifting distribution dynamics could affect GoodRx's competitive position.

The discount rate has risen slightly from 9.56% to 9.72%, reflecting a modest increase in perceived risk or required return.

The revenue growth expectation has fallen slightly from 5.74% to 5.59%.

The net profit margin estimate decreased modestly, moving from 10.49% to 10.34%.

The future P/E (Price to Earnings) multiple has risen marginally from 18.40x to 18.84x.

The fair value estimate remains unchanged at $5.09 per share.

Narratives on Simply Wall St turn raw numbers into living stories about a company. They connect what a business does today to a clear financial forecast, and then to a fair value estimate, all in one place. Hosted on the Community page and used by millions of investors, Narratives update dynamically as news and earnings hit, helping you compare Fair Value with the current share price.

Head over to the Simply Wall St Community and follow the Narrative on GoodRx Holdings to stay on top of:

How expanding pharma partnerships and digital health integrations could affect revenue growth, margins, and Fair Value.

Whether competitive pressures, PBM changes, and regulation might influence user growth and pricing power.

How updated forecasts for 5.8% annual revenue growth and rising margins are reflected relative to today’s price.

Follow the full story here: GoodRx Holdings Narrative on Simply Wall St.

Curious how numbers become stories that shape markets? Explore Community Narratives

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include GDRX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com